ExThera Medical Corporation

ExThera Medical Corporation develops and commercializes the Seraph® 100 Microbind® Affinity Blood Filter, a single-use, extracorporeal blood filtration device designed to reduce pathogen levels in the bloodstream for patients with life-threatening bloodstream infections, sepsis, and related critical care conditions. The Seraph 100 employs proprietary microbead adsorption media with chemically-bonded modified heparin to selectively bind and remove pathogens—including bacteria, viruses, and endotoxins—from circulating blood while leaving the blood itself intact in the filter. The technology has been studied for COVID-19 treatment and is now advancing into clinical trials for broader infectious disease applications and oncology-related conditions through pipeline programs including ONCObind®. The company is advancing Phase I clinical trials (OSCAR I) for bloodstream infection management and exploring applications in pancreatic cancer treatment. ExThera's extracorporeal blood purification approach addresses a critical unmet need in intensive care settings where pathogenic load reduction can improve outcomes in sepsis, severe infections, and related hemodynamic compromise. The company maintains regulatory development pathways and publishes peer-reviewed clinical and preclinical data. Manufacturing and quality systems support single-use, sterile device production for hospital and critical care deployment.